Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women
Open Access
- 10 June 2019
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 47 (7) , 3115-3126
Abstract
Objectives: To investigate the expression levels of aromatase cytochrome P450 enzyme (P450AROM) and related molecules—estrogen receptor-beta (ER-β), Ki-67, and p53—in prolactinoma tumor tissue from pre- and post-menopausal women, and to determine the associations of tumor invasiveness with expression levels of these genes. Methods: This study recruited 90 patients with prolactinoma who underwent adenoidectomy between 2012 and 2017. Information was collected regarding clinical characteristics, hormones, laboratory tests, and magnetic resonance imaging-assessed tumor invasiveness. Expression levels of P450AROM, ER-β, Ki-67, and p53 were examined by immunohistochemistry in prolactinoma tissues. Results: Increased P450AROM expression was found in invasive prolactinoma tissues in post-menopausal women, compared with its expression in non-invasive prolactinoma tissues. ER-β level was significantly higher in patients resistant to treatment with bromocriptine, a dopamine agonist. However, there were no differences in rate of resistance to treatment (8.2% vs. 3.4%) or expression levels of P450AROM, Ki-67, p53, and ER-β between pre- and post-menopausal patients. Conclusions: Our results demonstrated that increased P450AROM expression in prolactinoma of post-menopausal women was positively associated with invasiveness. Moreover, ER-β level was higher in both pre- and post-menopausal patients who were resistant to dopamine agonist treatment.Keywords
This publication has 37 references indexed in Scilit:
- Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomasJournal of Clinical Neuroscience, 2013
- Biomarkers of Pituitary Neoplasms: A Review (Part II)Neurosurgery, 2010
- KI-67 IN PITUITARY NEOPLASMSNeurosurgery, 2009
- Estrogen Receptors in Human Pituitary TumorsHormone and Metabolic Research, 2008
- Pathobiology of Pituitary Adenomas and CarcinomasNeurosurgery, 2006
- Guidelines of the Pituitary Society for the diagnosis and management of prolactinomasClinical Endocrinology, 2006
- Patterns of Gene Expression in Pituitary Carcinomas and Adenomas Analyzed by High-Density Oligonucleotide Arrays, Reverse Transcriptase-Quantitative PCR, and Protein ExpressionEndocrine, 2006
- Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonistsFertility and Sterility, 2005
- p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth FractionsNeurosurgery, 1996
- A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.Journal of Clinical Pathology, 1995